Cargando…

In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine

BACKGROUND: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H(1 )receptor without significant affi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howell, G, West, L, Jenkins, C, Lineberry, B, Yokum, D, Rockhold, R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1192807/ https://www.ncbi.nlm.nih.gov/pubmed/16109168 http://dx.doi.org/10.1186/1471-2210-5-13

Ejemplares similares

Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression
por: Apolloni, Savina, et al.
Publicado: (2016)

Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of In Vivo Drug-Receptor Binding
por: Yamada, Shizuo, et al.
Publicado: (2012)

Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence
por: Dahlman, Disa, et al.
Publicado: (2016)

Desloratadine Induced Pill Esophagitis
por: Alkim, Huseyin, et al.
Publicado: (2012)

Differential pharmacological and sex-specific effects of antimuscarinic agents at the hypoglossal motor nucleus in vivo in rats
por: Niakani, Sepehr, et al.
Publicado: (2022)

Use of Antimuscarinics in the Elderly
por: Patel, Bhavin, et al.
Publicado: (2009)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
por: Liao, Chun-Hou, et al.
Publicado: (2016)

In Vitro and In Vivo Characterization of the Transdermal Gel Formulation of Desloratadine for Prevention of Obesity and Metabolic Syndrome
por: Mohamed, Eman M., et al.
Publicado: (2023)

Antihistaminergic and Anticholinergic Properties of the Root Bark Aqueous Extract of Diospyros mespiliformis (Ebenaceae) on Hypersecretion of Gastric Acid Induced in Wistar Rats
por: Vandi, Vandza Luc, et al.
Publicado: (2022)

Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: A Review of the Evidence
por: Canonica, G. Walter, et al.
Publicado: (2011)

Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer
por: Ma, Jianfeng, et al.
Publicado: (2020)

Development and validation of an improved LC-MS/MS method for the quantification of desloratadine and its metabolite in human plasma using deutrated desloratadine as internal standard
por: Hasnain, M. Saquib, et al.
Publicado: (2013)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Optimization and Evaluation of Desloratadine Oral Strip: An Innovation in Paediatric Medication
por: Singh, Harmanpreet, et al.
Publicado: (2013)

Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria
por: Staevska, Maria T
Publicado: (2016)

Synthesis, characterization, and stability study of desloratadine multicomponent crystal formation
por: Ainurofiq, Ahmad, et al.
Publicado: (2018)

A Case of Recurrent Fixed Drug Eruption Secondary to Desloratadine
por: Almukhadeb, Eman
Publicado: (2021)

Bladder antimuscarinics and cognitive decline in elderly patients
por: Moga, Daniela Claudia, et al.
Publicado: (2017)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury
por: Han, Seok-Hee, et al.
Publicado: (2019)

Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study
por: Aberer, Werner
Publicado: (2009)

The antimuscarinic agent biperiden selectively impairs recognition of abstract figures without affecting the processing of non‐words
por: Toth, Monika, et al.
Publicado: (2021)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome
por: Xia, Liping, et al.
Publicado: (2021)

Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine
por: Glass, Daniel J, et al.
Publicado: (2003)

The effect of desloratadine on ischemia reperfusion induced oxidative and inflammatory renal injury in rats
por: Kocaturk, Huseyin, et al.
Publicado: (2020)

Improved survival in several cancers with use of H(1)-antihistamines desloratadine and loratadine
por: Fritz, Ildikó, et al.
Publicado: (2021)

Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo
por: Stevenson, Alexander J., et al.
Publicado: (2018)

Quantification of desloratadine in human plasma by LC-ESI-MS/MS and application to a pharmacokinetic study
por: Ponnuru, Venkata Suresh, et al.
Publicado: (2012)

Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells
por: Mullol, Joaquim, et al.
Publicado: (2011)

Efficacy of Oral Isotretinoin in Combination with Desloratadine in the Treatment of Common Vulgaris Acne in Vietnamese Patients
por: Van, Thuong Nguyen, et al.
Publicado: (2019)

Brain histamine H(1) receptor occupancy after oral administration of desloratadine and loratadine
por: Nakamura, Tadaho, et al.
Publicado: (2019)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of Substituted Desloratadines as Potent Arginine Vasopressin V2 Receptor Antagonists
por: Mu, Shuai, et al.
Publicado: (2014)

A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation
por: Ainurofiq, Ahmad, et al.
Publicado: (2018)

Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects
por: Boer, Jeltje, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h76ko5854bds2gpehq3bolro97